CYCLERION THERAPEUTICS, INC. (KRSA) Free cash flow 2018–2022
CYCLERION THERAPEUTICS, INC. (KRSA) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$40.6MFY2022 · since FY2018: -$100.9M → -$40.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2022 | -$40.6M | -11.2% |
| FY2021 | -$36.5M | +50.7% |
| FY2020 | -$74.0M | +32.2% |
| FY2019 | -$109.1M | -8.1% |
| FY2018 | -$100.9M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More KRSA financial trends
KRSA RevenueKRSA Net incomeKRSA Net marginKRSA Gross profitKRSA Gross marginKRSA Operating incomeKRSA Operating marginKRSA Operating cash flowKRSA Capital expendituresKRSA Return on equityKRSA Stock buybacksKRSA Dividends paidKRSA Total assetsKRSA Total liabilitiesKRSA Shareholders’ equityKRSA overview →